These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2015 related articles for article (PubMed ID: 28700715)

  • 1. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Mayhew AD; Page MJ; Ridao M; Tobías A; Catalá MA; Tabarés-Seisdedos R; Moher D
    Syst Rev; 2015 Feb; 4():19. PubMed ID: 25875125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
    Pringsheim T; Steeves T
    Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Leach MJ; Perez Algorta G
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Otasowie J; Castells X; Ehimare UP; Smith CH
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006997. PubMed ID: 25238582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
    Riera M; Castells X; Tobias A; Cunill R; Blanco L; Capellà D
    Psychopharmacology (Berl); 2017 Sep; 234(17):2657-2671. PubMed ID: 28631099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
    Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH
    CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
    Storebø OJ; Skoog M; Damm D; Thomsen PH; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008223. PubMed ID: 22161422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.